Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.63 |
| ▸ | PRKACA | P17612 | 7/20 | 0.60 |
| ▸ | GSK3B | P49841 | 7/20 | 0.60 |
| ▸ | GSK3A | P49840 | 6/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.60 |
| ▸ | CLK2 | P49760 | 5/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.60 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.60 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.60 |
| ▸ | PAK4 | O96013 | 3/20 | 0.60 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.60 |
| ▸ | CAMK2A | Q9UQM7 | 3/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552165 | 0.87 | NUDT14 (0.55) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL410257 | 0.87 | NUDT14 (0.55) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL24710755 | 0.86 | LRRK2 (0.51) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| Bromide SCHEMBL6865619 | 0.85 | NUDT14 (0.54) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL28057752 | 0.85 | RET (0.48) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL1896766 | 0.83 | STK3 (0.58) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL4352960 | 0.83 | LRRK2 (0.58) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL23917432 | 0.83 | LRRK2 (0.50) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL8107167 | 0.83 | FLT3 (0.46) | LRRK2PRKACAGSK3BGSK3ACDK5 | |
| SCHEMBL3787081 | 0.83 | SRC (0.50) | LRRK2PRKACAGSK3BGSK3ACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9572811-B2 | Treatment of dry eye | PRINCIPIA BIOPHARMA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9090621-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150182530-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-8962635-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962831-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-0888353-B1 | N-7-HETEROCYCLYL PYRROLO [2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2003-07-09 | — | — | EP | disclosed |
| US-6051577-A | TYROSINE INHIBITORS; BONE DISORDERS | NOVARTIS AG (CH) | 2000-04-18 | — | — | US | disclosed |
| EP-0888353-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO 2,3-D]PYRIDINES AND THEIR USE | Novartis AG (CH) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034895-A1 | NOVEL N-7-HETEROCYCLYL PYRROLO[2,3-D]PYRIDINES AND THEIR USE | NOVARTIS AG (CH) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997032879-A1 | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997028161-A1 | NOVEL PYRROLO[2,3-D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | LRRK2 560/4885PRKACA 216/4885GSK3B 456/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | LRRK2 560/4885PRKACA 216/4885GSK3B 456/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | LRRK2 2087/4885PRKACA 478/4885GSK3B 2296/4885 |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | LRRK2 796/4885PRKACA 198/4885GSK3B 616/4885 |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | LRRK2 714/4885PRKACA 836/4885GSK3B 3843/4885 |
| US-20150182530-A1 | TREATMENT OF DRY EYE | BTK, SYK, LYN | LRRK2 399/4885PRKACA 51/4885GSK3B 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.